伊布替尼-话题@MedSci

#伊布替尼#

88篇内容 | 4031人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1288746, encodeId=3c3a1288e4625, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=J Allergy Clin Immunol：伊布替尼或许能够预防食物过敏, objectType=article, longId=131169, objectId=3fd413116950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fd413116950, replyNumber=0, likeNumber=122, createdTime=2018-03-03, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fd413116950, moduleTitle=J Allergy Clin Immunol：伊布替尼或许能够预防食物过敏, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fd413116950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288745, encodeId=15571288e45a5, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=JAMA Oncol：影响伊布替尼完全响应率的基线因素研究, objectType=article, longId=130689, objectId=25d4130689d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25d4130689d8, replyNumber=0, likeNumber=62, createdTime=2018-02-28, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25d4130689d8, moduleTitle=JAMA Oncol：影响伊布替尼完全响应率的基线因素研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25d4130689d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288744, encodeId=30c11288e44b7, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：如何治疗伊布替尼并发症, objectType=article, longId=128033, objectId=8dd7128033e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd7128033e5, replyNumber=0, likeNumber=81, createdTime=2018-01-30, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd7128033e5, moduleTitle=Blood：如何治疗伊布替尼并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd7128033e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288743, encodeId=16a71288e43f1, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, objectType=article, longId=123311, objectId=ff8a12331154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff8a12331154, replyNumber=0, likeNumber=39, createdTime=2017-12-15, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff8a12331154, moduleTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff8a12331154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288742, encodeId=09321288e42c0, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, objectType=article, longId=123310, objectId=7e0a123310a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e0a123310a5, replyNumber=0, likeNumber=53, createdTime=2017-12-15, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e0a123310a5, moduleTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e0a123310a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288741, encodeId=14f11288e4111, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】伊布替尼联合纳武单抗对多种复发性淋巴瘤有效, objectType=article, longId=123208, objectId=da9a1232083b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9a1232083b, replyNumber=0, likeNumber=39, createdTime=2017-12-14, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9a1232083b, moduleTitle=【2017 ASH】伊布替尼联合纳武单抗对多种复发性淋巴瘤有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9a1232083b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288740, encodeId=46f31288e40dc, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量, objectType=article, longId=123152, objectId=40001231522f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40001231522f, replyNumber=0, likeNumber=35, createdTime=2017-12-14, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40001231522f, moduleTitle=【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40001231522f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288739, encodeId=952c1288e39f2, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, objectType=article, longId=123151, objectId=925712315133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925712315133, replyNumber=0, likeNumber=33, createdTime=2017-12-14, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925712315133, moduleTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925712315133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288738, encodeId=cfb31288e38f8, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, objectType=article, longId=122976, objectId=1b1f1229e69f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1f1229e69f, replyNumber=0, likeNumber=36, createdTime=2017-12-12, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1f1229e69f, moduleTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1f1229e69f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288737, encodeId=d06a1288e3716, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】CLARITY研究——伊布替尼联合Venetoclax疗法对复发难治性CLL患者疗效喜人, objectType=article, longId=122975, objectId=1c8b1229e548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8b1229e548, replyNumber=0, likeNumber=37, createdTime=2017-12-12, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8b1229e548, moduleTitle=【2017 ASH】CLARITY研究——伊布替尼联合Venetoclax疗法对复发难治性CLL患者疗效喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8b1229e548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288736, encodeId=c2a31288e36ac, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年, objectType=article, longId=122937, objectId=5e1a12293e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e1a12293e5c, replyNumber=0, likeNumber=36, createdTime=2017-12-12, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e1a12293e5c, moduleTitle=【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e1a12293e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288735, encodeId=5a981288e35b0, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】研究证实伊布替尼治疗过程中机会性感染风险极低, objectType=article, longId=122936, objectId=0e7d12293691, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e7d12293691, replyNumber=0, likeNumber=34, createdTime=2017-12-12, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e7d12293691, moduleTitle=【2017 ASH】研究证实伊布替尼治疗过程中机会性感染风险极低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e7d12293691)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288734, encodeId=51c31288e3470, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】凋亡抵抗以及NOTCH1基因状态对伊布替尼治疗预后的影响, objectType=article, longId=122935, objectId=add9122935f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add9122935f5, replyNumber=0, likeNumber=31, createdTime=2017-12-12, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add9122935f5, moduleTitle=【2017 ASH】凋亡抵抗以及NOTCH1基因状态对伊布替尼治疗预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=add9122935f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288733, encodeId=24861288e33e7, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者, objectType=article, longId=122934, objectId=8533122934c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8533122934c1, replyNumber=0, likeNumber=43, createdTime=2017-12-12, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8533122934c1, moduleTitle=【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8533122934c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288732, encodeId=94fc1288e32e5, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究, objectType=article, longId=122933, objectId=d3461229331a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3461229331a, replyNumber=0, likeNumber=35, createdTime=2017-12-12, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3461229331a, moduleTitle=【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3461229331a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288731, encodeId=74021288e31a1, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果, objectType=article, longId=122749, objectId=0a3a122e49ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a3a122e49ca, replyNumber=0, likeNumber=37, createdTime=2017-12-10, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a3a122e49ca, moduleTitle=【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a3a122e49ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288730, encodeId=d63e1288e303e, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, objectType=article, longId=122745, objectId=1ede122e4567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ede122e4567, replyNumber=0, likeNumber=41, createdTime=2017-12-10, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ede122e4567, moduleTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ede122e4567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288729, encodeId=1e501288e297f, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗, objectType=article, longId=122419, objectId=91ae12241903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91ae12241903, replyNumber=0, likeNumber=39, createdTime=2017-12-07, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91ae12241903, moduleTitle=【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91ae12241903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288728, encodeId=71d31288e2800, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, objectType=article, longId=122418, objectId=f1f41224182c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1f41224182c, replyNumber=0, likeNumber=41, createdTime=2017-12-07, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1f41224182c, moduleTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1f41224182c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288727, encodeId=f1a91288e27ab, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, objectType=article, longId=120735, objectId=9988120e352a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9988120e352a, replyNumber=0, likeNumber=46, createdTime=2017-11-21, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9988120e352a, moduleTitle=ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9988120e352a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊布替尼

2020-05-29

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

J Allergy Clin Immunol：伊布替尼或许能够预防食物过敏

2018-03-03

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

JAMA Oncol：影响伊布替尼完全响应率的基线因素研究

2018-02-28

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Blood：如何治疗伊布替尼并发症

2018-01-30

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT

2017-12-15

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著

2017-12-15

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】伊布替尼联合纳武单抗对多种复发性淋巴瘤有效

2017-12-14

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量

2017-12-14

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案

2017-12-14

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著

2017-12-12

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】CLARITY研究——伊布替尼联合Venetoclax疗法对复发难治性CLL患者疗效喜人

2017-12-12

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年

2017-12-12

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】研究证实伊布替尼治疗过程中机会性感染风险极低

2017-12-12

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】凋亡抵抗以及NOTCH1基因状态对伊布替尼治疗预后的影响

2017-12-12

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者

2017-12-12

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究

2017-12-12

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果

2017-12-10

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性

2017-12-10

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗

2017-12-07

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病

2017-12-07

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

ASH 2017】BCL2抑制剂venetoclax与伊布替尼联用治疗初诊未治高危和复发难治CLL的二期临床研究结果

2017-11-21

科室
- - 订阅+
  - 更多科室
工具
服务